Antithrombotic and antiplatelet activities of Soshiho-tang extract
© Lee et al.; licensee BioMed Central Ltd. 2013
Received: 4 December 2012
Accepted: 11 June 2013
Published: 18 June 2013
Soshiho-tang (SH; Chinese name, Xiao-Chai-Hu-Tang; Japanese name, Shosaiko-to) is a traditional Korean, Chinese, and Japanese medicine, which has been used to treat various conditions, including hepatitis, liver cirrhosis, and chronic and acute liver disease. SH consists of seven herbal components, of which Scutellaria baicalensis Georgi and Zingiber officinale Roscoe, are reported to have antithrombotic and antiplatelet activities. We investigated the antithrombotic activity of SH, including S. baicalensis and Z. officinale, as an integrative therapy.
To identify the antithrombotic activity of SH, we used a FeCl3-induced thrombus formation model. The mechanism of SH-mediated antithrombotic activity was assessed by determining platelet aggregation and coagulation times ex vivo, washed platelet aggregation, serotonin secretion, and thromboxane B2 formation.
SH prolonged the occlusion time of thrombus formation when applied in a FeCl3-induced thrombus formation model. SH also inhibited collagen-induced platelet aggregation ex vivo in a concentration-dependent manner; however, it did not affect coagulation. Hence, to identify the antiplatelet effect of SH, we investigated washed platelet aggregations in vitro. SH significantly inhibited various agonist-induced platelet aggregations, and it completely inhibited serotonin secretion and thromboxane B2 formation.
The findings suggest that SH inhibited FeCl3-induced thrombus formation through antiplatelet activity, including inhibition of platelet aggregation, and serotonin and TXB2 production. Thus, SH may be useful as an integrative herbal formula for the treatment of thrombosis.
KeywordsSoshiho-tang Antithrombotic activity Antiplatelet activity Serotonin secretion TXB2 formation
Thrombus formation is a pivotal event in the pathogenesis of cardiovascular disease. Platelets are critical in all phases of thrombus formation, including the initial steps of atherosclerosis, progression of fatty streaks to atherosclerotic lesions, and any resulting thrombotic complications . Presently, thrombotic disease is clinically treated by the administration of acetylsalicylic acid (aspirin), adenosine diphosphate (ADP) receptor blockers, and glycoprotein (GP) IIb/IIIa antagonists as directed to prevent cardiovascular disease ; however, they can have systemic hemorrhagic side effects . Thrombus formation is also directly connected to the initiation of coagulation in fibrin production. Blood coagulation factor VIIa (FVIIa) is important in tissue factor complex formation . Following tissue injury, membrane-bound tissue factor (TF) crucially binds to FVIIa and the binary FVIIa/TF complex (the extrinsic pathway), then generates FIXa (the intrinsic pathway) and FXa, which result in formation of the Xnase complex [5–7]. The Xnase complex, along with FVIIa/TF, converts FX to activated factor X, which assembles with activated factor V to form the prothrombinase complex that is directly responsible for the formation of thrombin .
In the atherosclerotic artery, platelets are activated to respond to injury by plaque rupture or erosion, which leads to the release of additional agonists, such as thromboxane (TX) A2, 5-hydroxytryptamine (serotonin), and ADP, which lead to further recruitment of platelets to injury sites [8–10]. TXA2 has several effects as it is the major contributor of platelet aggregation via collagen, which is the most atherogenic activator of the vessel wall . Meanwhile, serotonin is released from dense granules during platelet activation. In a previous report, serotonin was shown to play a role in platelet formation, and was related to the constriction and dilation of vascular vessels .
Soshiho-tang (SH) is a traditional Korean, Chinese, and Japanese medicine, and has been used to treat various conditions, including hepatitis, liver cirrhosis, and chronic and acute liver disease [13, 14]. Recent studies show that SH has various pharmacological properties, including immunomodulatory effects , modulation of liver fibrosis , and treatment of anti-interstitial pneumonia [13, 14]. However, the integrative effect of SH on antithrombotic and antiplatelet activity have not reported with regard to its seven herbal components, including Bupleurum falcatum Linne, Glycyrrhiza uralensis Fischer, Panax ginseng C.A. Meyer, Pinellia ternata Breitenbath, Scutellaria baicalensis Georgi, Zingiber officinale Roscoe, and Zizyphus jujuba Miller var. inermis Rehder. Among these components, S. baicalensis and Z. officinale have been reported to have antithrombotic and antiplatelet activity [17–19]. Hence, in this study, we investigated the antithrombotic activity through the antiplatelet effects of SH including the use of S. baicalensis and Z. officinale as integrative therapies.
Indomethacin, bovine serum albumin (BSA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), serotonin creatinine sulfate, o-phthalaldehyde (OPT), imipramine, acetylsalicylic acid (ASA, aspirin), and dimethyl sulfoxide (DMSO) were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Collagen, arachidonic acid (AA), ADP, and thrombin were purchased from Chrono-Log Co. (Havertown, PA, USA). Cephalin, thromboplastin, and bovine thrombin were purchased from Instrumentation Laboratory Co. (Milano, Italy). Other chemicals were of analytical grade.
Male Sprague–Dawley rats (250–300 g) and New Zealand white rabbits (2.5-3 kg) were purchased from Sam-Tako Animal Co. (Osan, Korea) and acclimated for 1 week at a temperature of 24 ± 1°C and humidity of 55 ± 5%. The animals had free access to a commercial pellet diet obtained from Samyang Co. (Wonju, Korea) and drinking water. The animal studies have been carried out in accordance with the Korea Institute of Oriental Medicine Care Committee Guidelines, and were approved by the Korea Institute of Oriental Medicine Care and Use Committee (Protocol # 12–056). The animals were cared for in accordance with the dictates of the National Animal Welfare Law of Korea.
Preparation of Soshiho-tang extract
Bupleurum Root, Glycyrrhizae Radix et Rhizoma, Ginseng Radix, Pinellia Tuber, Scutellaria Root, Zingiberis Rhizoma Crudus, and Zizyphi Fructus were purchased from Yeongcheon traditional herbal market (Yeongcheon, Korea). All voucher specimens were deposited in the herbal bank of the KM-Based Herbal Drug Research Group, Korea Institute of Oriental Medicine.
SH was prepared according to previously reported methods . Briefly, 1674.5 g of medicinal herbal drug, including Bupleurum Root 600 g, Glycyrrhizae Radix et Rhizoma 100 g, Ginseng Radix 200 g, Pinellia Tuber 200 g, Scutellaria Root 400 g, Zingiberis Rhizoma Crudus 74.5 g, and Zizyphi Fructus 100 g, was decocted with 16.745 L of boiling water in a stainless oven for 3 h at 115°C using a Gyeongseo Extractor Cosmos-600 (Incheon, Korea), after which the decoction was filtered using standard testing sieves (150 μm; Retsch, Haan, Germany). The filtrate was lyophilized and stored in desiccators at 4°C. The freeze-dried extract powder was then dissolved in 50% DMSO (v/v with phosphate-buffered saline) and filtered (pore size, 0.2 μm), then kept at 4°C for use.
Arterial thrombus formation in vivo
Male Sprague–Dawley rats (n = 7) were orally administered with SH (300 and 600 mg/kg) or ASA (100 mg/kg), a positive control, for 5 days, and then anaesthetized by intraperitoneal injection of pentobarbital (50 mg/kg). Arterial thrombus formation in vivo was investigated as previously described . Briefly, a segment of the right carotid artery was isolated and dissected free of the vagus nerve and surrounding tissues. Aortic blood flow was measured with a Blood FlowMeter (ADInstruments, Colorado Springs, CO, USA). Arterial thrombus formation was induced by wrapping a 2-mm2 Whatman Grade 1 filter paper, saturated with 50% ferric chloride (FeCl3; w/v, in distilled water), on the carotid artery near the probe for 10 min. The time needed for occlusion to occur was measured for up to 60 min, and occlusion time was assigned a value of 60 min for vessels that did not occlude within that time.
Platelet aggregation and coagulation times ex vivo
Ex vivo platelet aggregation was investigated as previously described . In brief, male Sprague–Dawley rats (n = 8) were orally administered with SH (300 and 600 mg/kg) and ASA (100 mg/kg) for 5 days, and blood was collected 60 min after the last administration. Platelet-rich plasma (PRP) was obtained by centrifuging the blood sample at 180 × g for 10 min, and platelet-poor plasma (PPP) was obtained by centrifuging the PRP at 2100 × g for 10 min continuously. PRP was adjusted to 4 × 108 platelets/ml with PPP. Platelet aggregation was measured with an aggregometer (Chrono-Log Co.), and collagen (3 μg/ml) and ADP (5 μM) were used as aggregation stimulators. The plasma-activated partial thromboplastin time (APTT) and prothrombin time (PT) were automatically measured with an Automated Coagulation Laboratory 100 Instrument (Instrumentation Laboratory) as previously described . In brief, PPP was incubated at 37°C for 7 min, and then 100 μl incubated plasma was mixed with 50 μl cephalin in the process plate. Coagulation was triggered by the addition of CaCl2 plus either 100 μl thromboplastin or 100 μl polibrene for the APTT and PT assays, respectively.
Washed rabbit platelet preparation and platelet aggregation in vitro
Blood was withdrawn from the ear artery of male New Zealand white rabbits and collected into 0.15 (v/v) of anticoagulant citrate dextrose (ACD) solution that contained 0.8% citric acid, 2.2% trisodium citrate, and 2% dextrose (w/v). Washed platelets were prepared as previously described . Briefly, PRP was obtained by centrifugation of rabbit blood at 230 × g for 10 min. Platelets were sedimented by centrifugation of the PRP at 800 × g for 15 min and washed with HEPES buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 5.6 mM glucose, and 3.8 mM HEPES, pH 6.5) containing 0.35% BSA and 0.4 mM EGTA. The washed platelets were suspended in HEPES buffer (pH 7.4) and adjusted to 4 × 108 cells/ml. Platelet aggregation was measured with an aggregometer (Chrono-Log Co.) according to Born’s turbidimetry method . Briefly, washed platelet suspension was incubated at 37°C in the aggregometer with stirring at 1200 rpm, and then various concentrations of SH were added. After 3 min preincubation, platelet aggregation was induced by the addition of collagen (3 μg/ml), AA (100 μM), or thrombin (0.05 U/ml).
Cell viability of platelets was determined as previously described . Cell death of platelets by SH treatment was detection using a Cell Counting Kit-8 according to the manufacturer’s instructions (Wako, Osaka, Japan). In vitro viability was determined by measuring reduced formazan, a colorimetric assay based on the reduction of tetrazolium salt by cellular NADH or NADPH. The working solution (10 μl) containing WST-1 and SH was added to the PRP (200 μl) containing 4 × 108 platelets/ml in a 96-well microtiter plate (Disposable Products, Adelaide, South Australia). The absorbance of the colored product (formazan dye) was read on a microplate reader (Well Reader SK601; Seikagaku, Tokyo, Japan) using a test wavelength of 450 nm against a reference wavelength of 650 nm.
Serotonin release was measured as previously described . In brief, to prevent the reuptake of secreted serotonin, imipramine (a serotonin reuptake inhibitor, 5 μM) was added to PRP. Washed rabbit platelets were treated with various concentrations of SH at 37°C for 3 min prior to the addition of an agonist (collagen 3 μg/ml, AA 100 μM, or thrombin 0.05 U/ml) for 5 min. An aliquot (0.35 ml) of the washed rabbit platelets was mixed with 5 mM EDTA on ice and centrifuged at 12,000 × g for 2 min. The supernatant was mixed with 6 M trichloroacetic acid (TCA) and centrifuged at 12,000 × g for 2 min. An aliquot (0.3 ml) of the TCA supernatant was mixed with 1.2 ml of the solution (0.5% o-phthalaldehyde in ethanol diluted 1:10 with 8 N HCl), placed in a boiling water bath for 10 min, and then cooled on ice. The excess lipids were extracted with chloroform, and the fluorophore was measured at excitation and emission wavelengths of 360 nm and 475 nm, respectively. Serotonin creatinine sulfate was used as the standard solution to calculate the extent of serotonin release.
Thromboxane B2 formation
Platelets were preincubated with SH or ASA at the indicated concentrations for 3 min and then exposed to collagen (3 μg/ml), AA (100 μM), or thrombin (0.05 U/ml), as in the aggregation assay. Ethylene glycol bis(2-aminoethyl ether) tetraacetic acid (EGTA, 2 mM) containing 0.1 M KCl and indomethacin (5 mM) were then added to platelet suspension. Thromboxane B2 (TXB2) level was measured with an enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions.
Results are expressed as means ± SEM, and were analyzed using Student’s t- test or an analysis of variance (ANOVA). The results were considered significant when P < 0.05.
Effect of SH on thrombus formation
Effect of SH on aggregation and coagulation times ex vivo
Effect of SH on washed rabbit platelet aggregation in vitro
Effect of SH on serotonin secretion
Effect of SH on thromboxane B2 formation
In the TXB2 formation assay, SH significantly inhibited collagen- (Figure 4D), AA- (Figure 4E), and thrombin (Figure 4F)-induced TXB2 formation. These results indicate that SH has an overall effect rather than a selective effect in platelet activation. In addition, ASA, a cyclooxygenase inhibitor, completely suppressed the production of TXB2 from AA by cyclooxygenase-1 activation.
In this study, we demonstrated two major findings: SH had an antithrombotic effect via antiplatelet activity, and the antiplatelet effect of SH involved the suppression of serotonin secretion and TXB2 production. These results suggests that SH may be used as an herbal formula to manage atherosclerosis and thrombotic disease, although it still needs further study with respect to its molecular mechanisms.
Activation and aggregation of platelets play an important role in thrombotic complications, such as atherosclerosis, stroke, myocardial infarction, and acute coronary syndromes [8–10]. In the clinical treatment for thrombotic diseases, inhibition of platelet activation leads to suppression of thrombosis formation and progression, and therefore, it is an important target for preventing complications after an acute coronary incident . Generally, platelet aggregation and activation are mainly mediated through adhesion of platelets to the site of injury, and through the action of endogenous agonists such as collagen, ADP, and thrombin, followed by the release of TXA2 and serotonin, which act as amplification factors in platelet aggregation [25, 26].
In this study, SH significantly prolonged the occlusion time of thrombus formation when applied in a FeCl3-induced thrombus formation model. Our results show that SH, at a concentration of up to 300 mg/kg, had an equivalent effect to ASA, although SH was administered at a higher dose than ASA (Figure 1).
SH inhibited collagen-induced platelet aggregation ex vivo (Figure 2A) in a concentration-dependent manner without affecting coagulation, including APTT and PT (Figure 2B), indicating that SH inhibits thrombus formation by antiplatelet activity rather than anticoagulant activity.
Accordingly, we investigated the effect of SH on various agonist-induced platelet aggregations to identify the antiplatelet activity. SH potently inhibited collagen-, AA-, and thrombin-induced platelet aggregation in a concentration-dependent manner (Figure 3) without cellular cytotoxicity (Figure 3E). In platelet activation, serotonin secretion is the indicator to identify the levels of platelet activation because serotonin is released from activated platelets during platelet aggregation . SH significantly inhibited collagen-, AA-, and thrombin-induced serotonin secretion as well as agonist-induced TXB2 formation (Figure 4). TXA2, as the active form of TXB2, is the major contributor to platelet aggregation and activation . Inhibition of serotonin and thromboxane B2 production in our results indicate that inhibition of platelets by SH may be an overall effect rather than a selective effect of platelet activation.
Additionally, the protective effects of S. baicalensis and Z. officinale, which are components of SH, have been reported in cardiovascular disease [17–19]. In a previous report, S. baicalensis prolonged thrombus formation by 23.79% due to its antithrombotic activity, and inhibited platelet aggregation by 45.52% due to its antiplatelet activity . Also, Z. officinale a bioactive ginger, reportedly could have antiplatelet activity . In comparison to previous results on the individual components of SH, our study suggests that SH has a complementary effect whereby all of the components work together to create an improved antithrombotic effect.
Taken together, this study suggests that SH, which contains S. baicalensis and Z. officinale, inhibited thrombus formation through antiplatelet activity, resulting in the inhibition of platelet aggregation and suppression of serotonin and TXB2 production.
Anticoagulant citrate dextrose
Activated partial thromboplastin time
Bovine serum albumin
Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid
This work was supported by grant K13050 awarded to the Korea Institute of Oriental Medicine (KIOM) from the Ministry of Education, Science and Technology (MEST), Republic of Korea.
The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/FGzTiX.
- Steinhubl SR, Moliterno DJ: The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs. 2005, 5 (6): 399-408. 10.2165/00129784-200505060-00007.View ArticlePubMed
- Lange RA, Hillis LD: Antiplatelet therapy for ischemic heart disease. N Engl J Med. 2004, 350 (3): 277-280. 10.1056/NEJMe038191.View ArticlePubMed
- Serebruany VL, Malinin AI, Eisert RM, Sane DC: Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004, 75 (1): 40-47. 10.1002/ajh.10451.View ArticlePubMed
- Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B: Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood. 2004, 104 (10): 3190-3197. 10.1182/blood-2004-03-0935.View ArticlePubMed
- Furie B, Furie BC: The molecular basis of blood coagulation. Cell. 1988, 53 (4): 505-518.View ArticlePubMed
- Mann KG: Biochemistry and physiology of blood coagulation. Thromb Haemost. 1999, 82 (2): 165-174.PubMed
- Monroe DM, Hoffman M, Roberts HR: Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002, 22 (9): 1381-1389. 10.1161/01.ATV.0000031340.68494.34.View ArticlePubMed
- Majid A, Delanty N, Kantor J: Antiplatelet agents for secondary prevention of ischemic stroke. Ann Pharmacother. 2001, 35 (10): 1241-1247.View ArticlePubMed
- Brass LF: Thrombin and platelet activation. Chest. 2003, 124 (3 Suppl): 18S-25S.View ArticlePubMed
- Ruggeri ZM: Platelets in atherothrombosis. Nat Med. 2002, 8 (11): 1227-1234. 10.1038/nm1102-1227.View ArticlePubMed
- Gibbins JM: Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci. 2004, 117 (Pt 16): 3415-3425.View ArticlePubMed
- Jonnakuty C, Gragnoli C: What do we know about serotonin?. J Cell Physiol. 2008, 217 (2): 301-306. 10.1002/jcp.21533.View ArticlePubMed
- Daibo A, Yoshida Y, Kitazawa S, Kosaka Y, Bando T, Sudo M: A case of pneumonitis and hepatic injury caused by a herbal drug (sho-saiko-to). Nihon Kyobu Shikkan Gakkai Zasshi. 1992, 30 (8): 1583-1588.PubMed
- Kawasaki A, Mizushima Y, Kunitani H, Kitagawa M, Kobayashi M: A useful diagnostic method for drug-induced pneumonitis: a case report. Am J Chin Med. 1994, 22 (3–4): 329-336.View ArticlePubMed
- Huang XX, Yamashiki M, Nakatani K, Nobori T, Mase A: Semi-quantitative analysis of cytokine mRNA expression induced by the herbal medicine Sho-saiko-to (TJ-9) using a Gel Doc system. J Clin Lab Anal. 2001, 15 (4): 199-209. 10.1002/jcla.1028.View ArticlePubMed
- Chen MH, Chen JC, Tsai CC, Wang WC, Chang DC, Tu DG, Hsieh HY: The role of TGF-beta 1 and cytokines in the modulation of liver fibrosis by Sho-saiko-to in rat's bile duct ligated model. J Ethnopharmacol. 2005, 97 (1): 7-13. 10.1016/j.jep.2004.09.040.View ArticlePubMed
- Zhang Y, Wang X, Xu Z, Liu Z, Ni Q, Chu X, Qiu M, Zhao A, Jia W: Protective effect of flavonoids from Scutellaria baicalensis Georgi on cerebral ischemia injury. J Ethnopharmacol. 2006, 108 (3): 355-360. 10.1016/j.jep.2006.05.022.View ArticlePubMed
- Liao YR, Leu YL, Chan YY, Kuo PC, Wu TS: Anti-platelet aggregation and vasorelaxing effects of the constituents of the rhizomes of Zingiber officinale. Molecules. 2012, 17 (8): 8928-8937.View ArticlePubMed
- Nie H, Meng LZ, Zhang H, Zhang JY, Yin Z, Huang XS: Analysis of anti-platelet aggregation components of Rhizoma zingiberis using chicken thrombocyte extract and high performance liquid chromatography. Chin Med J (Engl). 2008, 121 (13): 1226-1229.
- Lee JJ, Jin YR, Yu JY, Munkhtsetseg T, Park ES, Lim Y, Kim TJ, Pyo MY, Hong JT, Yoo HS: Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug. Atherosclerosis. 2009, 206 (2): 375-382. 10.1016/j.atherosclerosis.2009.02.034.View ArticlePubMed
- Born GV, Cross MJ: The aggregation of blood platelets. J Physiol. 1963, 168: 178-195.PubMed CentralView ArticlePubMed
- Lee JJ, Yu JY, Lee JH, Zhang WY, Kim TJ, Myung CS, Yun YP: The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase. Arch Pharm Res. 2010, 33 (3): 387-394. 10.1007/s12272-010-0307-1.View ArticlePubMed
- Nishihira K, Yamashita A, Tanaka N, Kawamoto R, Imamura T, Yamamoto R, Eto T, Asada Y: Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J Thromb Haemost. 2006, 4 (1): 247-255. 10.1111/j.1538-7836.2005.01702.x.View ArticlePubMed
- Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J: Guidelines on myocardial revascularization. Eur Heart J. 2010, 31 (20): 2501-2555.View ArticlePubMed
- Jackson SP, Nesbitt WS, Kulkarni S: Signaling events underlying thrombus formation. J Thromb Haemost. 2003, 1: 1602-1612. 10.1046/j.1538-7836.2003.00267.x.View ArticlePubMed
- Farndale RW, Sixma JJ, Barnes MJ, De Groot PG: The role of collagen in thrombosis and hemostasis. J Thromb Haemost. 2004, 2: 561-573. 10.1111/j.1538-7836.2004.00665.x.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/13/137/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.